To assess the use of a suicide gene and evaluate activation process impact in cells from leukemic donors, RapaCasp9-G-expressing GMTCs were also produced from AML patients with a sufficient transduction efficiency in both IL-2 and IL-7/-15 conditions (Fig. 5B top). The gene discussed is IL2; the disease is acute myeloid leukemia.